Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
13,886
Total Claims
$1.3M
Drug Cost
1,367
Beneficiaries
$934
Cost/Patient
Risk Score Breakdown 6/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-34%
Cost per patient vs peers
$934 vs $1,411 avg
+19%
Brand preference vs peers
12.6% vs 10.6% avg
Brand vs Generic
Brand: 1,732 claims · $968K
Generic: 11,984 claims · $300K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 97 | $135K |
| Semaglutide | 67 | $100K |
| Empagliflozin | 57 | $82K |
| Apixaban | 59 | $69K |
| Insulin Glargine,hum.Rec.Anlog | 90 | $61K |
| Rivaroxaban | 43 | $52K |
| Dulaglutide | 13 | $29K |
| Insulin Nph Hum/Reg Insulin Hm | 26 | $27K |
| Mirabegron | 26 | $25K |
| Insulin Glargine,hum.Rec.Anlog | 33 | $25K |
| Tirzepatide | 15 | $19K |
| Levothyroxine Sodium | 953 | $18K |
| Insulin Detemir | 21 | $18K |
| Insulin Glargine,hum.Rec.Anlog | 21 | $16K |
| Umeclidinium Brm/Vilanterol Tr | 14 | $14K |
Prescribing Profile
Patient Profile
73
Avg Age
70%
Female
1.25
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data